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Abstract 
Background 
Renal transplantation is the best treatment for kidney failure, in terms of length and quality 
of life and cost-effectiveness. However, most transplants fail after 10 to 12 years, consigning 
patients back onto dialysis. Damage by the immune system accounts for approximately 50% 
of failing transplants and it is possible to identify patients at risk by screening for the 
presence of antibodies against human leukocyte antigens. However, it is not clear how best 
to treat patients with antibodies. This trial will test a combined screening and treatment 
protocol in renal transplant recipients. 
Methods/design 
Recipients >1 year post-transplantation, aged 18 to 70 with an estimated glomerular 
filtration rate >30 mL/min will be randomly allocated to blinded or unblinded screening 
arms, before being screened for the presence of antibodies. In the unblinded arm, test results 
will be revealed. Those with antibodies will have biomarker-led care, consisting of a change 
in their anti-rejection drugs to prednisone, tacrolimus and mycophenolate mofetil. In the 
blinded arm, screening results will be double blinded and all recruits will remain on current 
therapy (standard care). In both arms, those without antibodies will be retested every 8 
months for 3 years. The primary outcome is the 3-year kidney failure rate for the antibody-
positive recruits, as measured by initiation of long-term dialysis or re-transplantation, 
predicted to be approximately 20% in the standard care group but <10% in biomarker-led 
care. The secondary outcomes include the rate of transplant dysfunction, incidence of 
infection, cancer and diabetes mellitus, an analysis of adherence with medication and a 
health economic analysis of the combined screening and treatment protocol. Blood samples 
will be collected and stored every 4 months and will form the basis of separately funded 
studies to identify new biomarkers associated with the outcomes. 
Discussion 
We have evidence that the biomarker-led care regime will be effective at preventing graft 
dysfunction and expect this to feed through to graft survival. This trial will confirm the 
benefit of routine screening and lead to a greater understanding of how to keep kidney 
transplants working longer. 
Trial registration 
Current Controlled Trials ISRCTN46157828. 
Keywords 
Human leukocyte antigen antibodies, renal transplantation, premature allograft failure, 
chronic rejection, screening, tacrolimus, mycophenolate mofetil, clinical trial, randomised 
controlled trial, randomized controlled trial, KCTU, CTU, trials unit, diabetes, kidney, graft 
failure, biomarker, biomarker-led care, DSA, non-DSA, multicentre, immunosuppression, 
usual care, treatment as usual, standard care, blinded, unblinded, EME funded, NIHR, 
optimised, optimized, intention-to-treat, per protocol 
Background 
The problem addressed by this study is premature transplant failure – kidney transplants do 
not last for the natural lifespan of most recipients. Premature in this context refers to the 
lifespan of the recipient.a Current death-censored 10-year transplant survival rates vary 
between 59% and 70%, so 30% to 40% of patients have their transplant for <10 years [1]. 
Since 2000, a consistent annual attrition rate of around 3% of kidney transplants [2] means 
that approximately 700 patients return to dialysis each year in the United Kingdom. Although 
many of these patients are eligible for a second transplant, the legacy of the first often makes 
it harder to find a well-matched second kidney. In addition, second (and any subsequent) 
transplants have a shorter lifespan than the original transplant, so the problem of premature 
failure becomes amplified. Of the various reasons why transplanted kidneys fail, the single 
most common cause is immune-mediated injury [3]. 
Two types of study have linked antibodies (Ab) against human leukocyte antigen (HLAs) to 
immune-mediated injury and premature graft failure. Case–control studies have compared 
patients who have lost grafts with those in whom grafts are still working, performing 
retrospective analysis of prospectively collected serum samples. For instance, Mizutani et al. 
[4] studied 39 patients with failed grafts due to chronic rejection (CR) and 26 matched 
controls with functioning grafts. In the former group, 72% had immunoglobulin G (IgG) 
HLA Ab, compared to 46% of controls. Similar results were obtained from a different study 
of a separate population [5]. The surprising thing from these studies was the high incidence of 
HLA Ab in patients with working grafts. There are several potential explanations for this. It 
is possible that factors relating to the HLA Ab (such as complement fixing ability) or factors 
in addition to the Ab, influence the progression of CR and thus the timing of eventual graft 
rejection. A second, related possibility, is that all patients with HLA Ab develop pathology, 
but it progresses at different rates, such that patients showing up in the control groups in these 
studies are deteriorating more slowly. Evidence for this comes from Mizutani et al. [4], who 
showed that their CR group with HLA Ab showed progressive deterioration of renal function 
prior to graft failure. The same progressive deterioration was seen in the control group of 
patients with HLA Ab, whose grafts did not fail. These data illustrate that CR is a time-
dependent process in which progressive graft dysfunction precedes graft failure. Moreover, 
the time from development of HLA Ab to graft failure is highly variable in different people. 
Separate studies have reported the prospective follow-up of outcomes in those with HLA Ab. 
Terasaki and Ozawa [6] studied 2,231 patients. In a group of 479 with HLA Ab, the 2-year 
graft failure rate was 15%, compared to 6.8% in the 1,753 with no HLA Ab. This trial noted 
that the patients who failed within 2 years had worse renal function on testing than those that 
did not, consistent with the fact that CR is a progressive and time-dependent process and 
those that fail are at the end of this process. In another study, the same group [7] reported that 
the 4-year survival rate for 1,329 patients, all with functioning transplants, was 58% for those 
with HLA Ab (158 patients) vs 81% for those without (806). 
Lachmann et al. [8] performed the best study to date. The study was based at a single centre 
in Berlin and had 1,014 patients with stable kidney function (for the 6 months pre-
recruitment) and were on average 6 years post-transplantation. Patients were tested for HLA 
Ab and prospectively followed for 5½ years. Grafts failed in 37% of the 302 who had HLA 
Ab, but in only 17% of the 712 patients who tested negative for HLA Ab. Moreover, in this 
latter group, a subgroup of 195 patients had a repeat test performed 2½ years into the study. 
Of these, 148 remained negative and only 6% of grafts failed in this group. In contrast, 47 
had developed new HLA Ab since the beginning of the study and 21% of these suffered graft 
failure, confirming that the development of new HLA Ab in the negative group was 
predictive of future graft loss. Finally, this study identified a difference between the 
prognostic value of HLA Ab that were specific for the donor, known as donor-specific 
antibodies (DSA), which were found in 33% of HLA Ab + patients, and those that were not 
(non-DSA), found in 66%. Graft failure rates were 51% over 5.5 years in patients with DSA 
and 30% in patients with non-DSA. In a subgroup of patients who had transplant biopsies, 
78% of those with failed grafts and HLA Ab + had changes consistent with CR. They 
concluded that grafts in patients with HLA Ab were more than three times likely to fail than 
those without, even when corrected for age, sex, year of transplant, estimated glomerular 
filtration rate (GFR) and number of previous kidney transplants. These findings have been 
corroborated by a second study from the Netherlands [9], in which the risk of graft failure 
with HLA Ab was also shown to be independent of graft dysfunction and proteinuria. 
Therefore, the literature indicates that HLA Ab are a prognostic biomarker and could be used 
as a screening test to identify patients at high risk of premature kidney transplant failure. All 
transplant units in the United Kingdom have the ability to detect HLA Ab, but routine 
systematic post-transplant screening of patients has not been generally adopted because it is 
not clear how best to treat patients once identified. Although there is a widespread view in the 
literature that HLA Ab cause CR, there is no evidence of this in humans. The chief 
investigator’s group has been investigating patients with CR for several years and has 
evidence that the activity of T and B cells is most strongly associated with progression of CR 
and that this subgroup benefits from enhanced immunosuppression (Shiu et al., manuscript in 
preparation). This study will therefore test a combined screening and treatment protocol for 
HLA Ab in a randomised controlled trial. 
Methods/design 
Trial objectives 
Primary objective 
The primary objective is the 3-year graft failure rate for patients testing positive for HLA Ab 
at baseline or within 3 years of randomisation who receive an optimised anti-rejection 
medication intervention with prednisone, tacrolimus (tac) and mycophenolate mofetil (MMF) 
(treatment), compared to a control group who test positive for HLA Ab at baseline or within 
3 years post-randomisation who remain on their established immunotherapy and whose 
clinicians are not aware of their Ab status. 
Secondary objectives 
Determine the 3-year graft failure rate in patients randomised to unblinded HLA Ab 
screening, compared to a control group randomised to blinded HLA Ab screening. 
Determine whether the treatment influences patient survival. 
Determine whether the treatment influences the development of graft dysfunction as assessed 
by the presence of proteinuria (protein/creatinine ratio (PCR) > 50) or a change in the 
estimated glomerular filtration rate (eGFR). 
Determine whether the treatment influences the rate of acute rejection for these groups. 
Determine the adverse effect profiles of treatment in this group, in particular whether they are 
associated with increased risk of infection, malignancy or diabetes mellitus (DM). 
Determine the cost-effectiveness of routine screening for HLA Ab and prolonging transplant 
survival using this screening and treatment protocol. 
Determine the impact of biomarker screening and the treatment on the patients’ adherence to 
drug therapy and their perceptions of the risk to the health of the transplant. 
Collect regular samples from patients enrolled in the HLA Ab + groups to enable an in-depth 
scientific analysis of the HLA Ab and cells of the immune and repair systems and to develop 
more sophisticated biomarkers for progression and/or responsiveness to therapy (to be funded 
separately, not as part of the efficacy and mechanism evaluation (EME) programme). 
Primary end points 
The primary end point is the 3-year graft failure rate in HLA Ab + patients. Graft failure will 
be defined as restarting long-term dialysis or requiring a new transplant. Time zero starts at 
the time of randomisation, once the result of the HLA test is known. For those patients who 
are HLA Ab– at randomisation but become Ab + during a subsequent screening, time zero 
will be reset at the time of the positive test, and the follow-up time will be extended to allow 
for the 3-year end point. 
Secondary end points 
The secondary clinical end points are: 
• 3-year graft failure rates in all patients recruited to the trial 
• Patient survival 
• Rate of progression of graft dysfunction, as assessed by the change in the degree of 
proteinuria (PCR > 50) or the change in estimated GFR over 3 years 
• Rate of biopsy-proven rejection over 3 years 
• Rates of culture- or polymerase chain reaction-positive infection, biopsy-proven 
malignancy and DM 
• Health economic analysis of outcomes 
• Analysis of adherence and perceptions of risk for the biomarker-led care (BLC) groups 
• The secondary scientific end points are: 
• Changes in characteristics of HLA Ab and laboratory parameters of T and B cell 
phenotypes and responsiveness for the HLA Ab + groups 
• Change in numbers and phenotype of circulating CD34+ cells for the HLA Ab + groups 
Trial design 
This is a prospective open-labelled randomised marker-based strategy trial, with a standard 
control, where biomarker stratification is based on HLA Ab status. The biomarker-strategy 
design is appropriate for testing the clinical utility of a biomarker [10]. Recruitment will take 
place in five British renal transplant units over 3 years, with recruits followed for at least 3 
years. The trial design is shown in the flow diagram in Figure 1, which shows the number of 
patients anticipated to be in each group by the end of the trial, based on sample size 
calculations, consent rates, eligibility and estimated attrition. Recipients of cross-match 
negative transplants aged 18 to 70, >1 year post-transplant with eGFR ≥ 30 will be asked to 
give consent for the screening/treatment process. 
Figure 1 OuTSMART flow diagram. *Randomisation is performed using the results of a 
recruit’s first screening test. Those with donor specific antibodies (DSA) undergo no further 
screening as part of the trial (but serum will be stored for analysis of human leukocyte 
antigen antibody profiles later). †Those initially HLA Ab– undergo routine screening every 8 
months. There is no second randomisation. A recruit allocated to blinded standard care 
(group C) who becomes HLA Ab + (black lines) will remain in a standard care group (group 
A1 or A2). If in the unblinded standard care group (D), they will change to unblinded 
biomarker-led treatment care (group B1 or B2) (orange lines). ‡ The numbers in each group 
are those anticipated at the primary end point. Ab, antibodies; DSA, donor-specific 
antibodies; HLA, human leukocyte antigen; MMF, mycophenolate mofetil; tac, tacrolimus. 
The first stratification will be based on blood test screening for HLA Ab. Approximately 30% 
will be HLA positive, with approximately 70% negative. HLA Ab + patients will be further 
screened with single-antigen beads (SAB) to determine whether DSA are present 
(approximately will have 1/3 DSA and 2/3 non-DSA). Thus, biomarker stratification has 
three arms (DSA+, non-DSA + and HLA Ab–). The second stratification will be based on 
current immunosuppression to ensure balanced numbers already on tac or MMF in each 
group. The immunosuppression stratification has four groups: MMF only, tac only, both tac 
and MMF, and neither tac nor MMF. The third stratification factor will be the recruiting 
study site (five sites). 
HLA Ab + patients will be randomised 1:1 into either blinded standard care (SC) or 
unblinded BLC. Patients in the former (groups A1 and A2 in Figure 1) will be blind to their 
biomarker status and will remain on baseline immunotherapy, whereas the clinicians of 
patients in the latter (groups B1 and B2 in Figure 1) will know their HLA Ab status and will 
be offered treatment. HLA Ab– patients will remain on their existing immunotherapy and 
randomised 1:1 into either the blinded (C) or unblinded group (D), with only the latter 
knowing their HLA Ab status. Both these groups will receive regular Ab status monitoring 
for the first 3 years. Those patients who become positive during subsequent screening rounds 
(approximately 10% per year) will be moved to the appropriate HLA Ab + groups (DSA + or 
non-DSA+) for final data analysis. All patients in group D found to be positive on the second 
or subsequent rounds will be offered the same treatment as those patients who were positive 
in the first screening round, and followed up for 3 additional years from the time they become 
positive. Thus, the maximum amount of time any single patient can remain in the study is 6 
years. ‘New’ patients, randomised but initially HLA negative at baseline, will be included in 
the intended primary analysis of HLA positive groups at each successive 8 monthly screening 
round. The patient flow diagram according to CONSORT guidelines is provided as Figure 2. 
Figure 2 Consort diagram for OuTSMART. Ab, antibody; HLA, human leukocyte 
antigen. 
Sample size calculations {2nd level heading} 
The primary purpose of this trial is to demonstrate superior outcomes using a defined 
treatment strategy compared to standard care for biomarker (HLA Ab) positive patients. Once 
superiority is demonstrated for HLA Ab + patients, it is also necessary to demonstrate non-
inferior outcomes when comparing the unblinded screening strategy to the blinded standard 
of care for the entire patient population, including those HLA Ab–. The graft failure rate 3 
years after screening has been chosen as a clinically relevant primary outcome. As a reference 
for power calculations, we have used the observed failure rates reported by Lachmann et al. 
[8] for HLA Ab + and HLA Ab– patients. Since failure rates differ between DSA + and non-
DSA + patients, sample size calculations have been carried out separately for these groups. 
Following these calculations, we estimated the number to be screened, based on expected 
dropout rates, expected screening results and eligibility criteria (see below). We based our 
estimates of the differences in primary outcome between the groups on, first, the results of 
our preliminary data from patients with CR treated with a similar regime as used here, and 
second, our assessment that large differences in primary outcome will be needed to make the 
screening programme cost-effective. 
Hypothesis testing will be sequential [11]. Superiority will be tested first in the HLA Ab + 
groups to demonstrate the efficacy of the treatment. If this analysis is significant, then non-
inferiority will be tested for the entire population to demonstrate the clinical utility of the 
biomarker screening. We calculated the sample size needed to show the superiority of the 
treatment optimisation for biomarker-positive patients using the hypotheses as follows. 
Hypothesis 1.1: HLA Ab + patients with DSA, randomised to standard care (A1) will show 
higher graft failure rates than patients randomised to biomarker-led care (B1). 
We hypothesise that the experimental treatment will bring the failure rate of group B1 down 
to that of non-DSA patients in standard care (A2). Assuming a 30% failure rate for group A1 
(as in [8]), and a 16% failure rate for group B1, 139 patients per group will provide 80% 
power and 5% type I errors, for a two-sided test. 
Hypothesis 1.2: HLA Ab + patients, with non-DSA, randomised to standard care (A2) will 
show higher graft failure rate than patients randomised to biomarker-led care (B2). 
We hypothesise that the experimental treatment will bring the failure rate of group B2 down 
to that of biomarker negative patients in standard care (C). Assuming a 16% failure rate for 
group A2 (as in [8]), and a 6% failure rate for group B2, 146 patients per group will provide 
80% power and 5% type I errors, for a two-sided test. 
The numbers enrolled in groups A and B include those patients initially enrolled in groups C 
or D who become HLA Ab + during re-screening. 
We calculated the sample size needed to show the non-inferiority of all unblinded patients 
compared to all blinded patients as follows. 
Hypothesis 2: All patients randomised to unblinded screening (combined groups B1 + B2 + 
D) will show equal or lower graft failure rates than all patients randomised to blinded 
screening (combined groups A1 + A2 + C), irrespective of biomarker status. 
At the end of the trial, we expect 60% of patients to be in the HLA Ab– groups, 13% in DSA 
+ groups and 27% in non-DSA + groups (after dropouts). Assuming a 6% failure rate in 
biomarker negative groups C and D, the estimated average failure rate of all blinded 
screening patients is 11.8% (that is, (6 × 0.6) + (16 × 0.27) + (30 × 0.13)). Similarly, the 
estimated average failure rate in the unblinded screening group is 7.3%. We have established 
a non-inferiority limit of 5% absolute difference, so that the unblinded group would be 
considered non-inferior with a failure rate of 16.8% or lower. For this purpose, 1,043 patients 
in each arm would provide 90% power and 2.5% (one-sided) type I errors. 
We will keep recruiting until every group has acquired the number required to test both 
hypotheses. When calculating the number of patients to screen for eligibility and to recruit, 
the following assumptions were made: (1) 60% of patients under follow-up at each transplant 
centre will meet the eligibility criteria, (2) 10% will refuse consent, (3) the prevalence of 
HLA Ab in most transplant populations is 25% to 30%, (4) 6% of initially Ab– patients will 
become Ab + in each screening round and (5) 2% will drop out every screening round. 
Based on these assumptions and a recruitment audit in participating centres, we have 
estimated that we need to assess eligibility for 4,672 patients and enrol 2,522 to ensure 
sufficient numbers are in each group at the primary end point to test both hypotheses. Figure 
1 shows the number of patients needed in each of the arms to reach the primary end point to 
test hypothesis 2, which is sufficient to test hypotheses 1.1 and 1.2 (the numbers in groups A 
and B include those patients initially enrolled in groups C or D who were found to be HLA 
Ab + during re-screening). 
A recruitment audit has revealed that there is a very high chance of recruiting all the required 
patients from five participating centres within 3 years. We anticipate recruiting sufficient 
numbers of patients to all groups by screening round 3 or 4. Each centre is expected to recruit 
similar numbers of patients. 
Statistical analysis 
Primary analysis 
Statistical analysis will be on an intention-to-treat and treatment-received basis. We will 
consider the patients who become positive during the follow-up in the appropriate group. 
The proportion of graft failures for each of the groups is denoted by πA1, πB1, etc. 
Superiority (hypothesis 1): 
H0: πA1 = πB1 and πA2 = πB2 
H1: πA1 ≠ πB1 and πA2 ≠ πB2 
To test superiority for the primary outcome for the biomarker (HLA Ab) positive groups 
(hypotheses 1.1 and 1.2), we will use a two-sided Z-test at the 5% level of significance, and 
will calculate the 95% CI for the difference in the proportion of graft failures between the 
biomarker-led care and standard care groups. The biomarker-led care groups will be 
considered superior if the absolute Z > 1.96, and our assumptions with respect to the size of 
the differences will supported if the CI includes a positive difference in proportions of 14% 
for hypothesis 1.1, and 10% for hypothesis 1.2. 
Non-inferiority (hypothesis 2): 
H0: πUnblind – πBlind ≥ δ 
H1: πUnblind – πBlind < δ 
To test for non-inferiority of the unblinded groups compared to the blinded groups 
(hypothesis 2), we will carry out a one-sided Z-test at the 2.5% level of significance. We will 
conclude non-inferiority if H0 is rejected, and the corresponding upper bound of the 95% CI 
excludes the limit δ (set at 5% more failures in the unblinded groups). 
Secondary analysis 
A similar procedure will be followed for secondary binary outcomes. We will use Cox 
proportional hazards regression to analyse survival outcomes. For continuous secondary 
outcomes we will use a two-sample t-test, transforming data where they are skewed. 
Exploratory moderator analysis 
Additionally, for all primary and secondary analyses, we will carry out multivariable 
analyses, using generalised linear models, to adjust for the effects of stratification factors (for 
example, the previous immunosuppression regime). In this case, we will use the 
corresponding odds ratio to evaluate the adjusted size of the differences between proportions, 
by transforming back the estimated odds ratio associated with the treatment group into 
absolute differences in proportions. If the results of the analysis of the primary outcome are 
significantly affected, the adjusted effects will be taken as final. 
Handling missing data 
Where a given outcome is measured at two or more time points, missing post-randomisation 
assessments will be dealt with by fitting linear mixed models to all the available measures 
using maximum likelihood methods. Such an approach provides valid inferences under the 
assumption that the missing data mechanism is ignorable (or Missing at Random). If post-
randomisation variables are found to be predictive of the dropout rate, multiple imputation 
will be considered using K-nearest neighbours. 
Economic evaluation 
Cost data is usually skew but will be analysed using arithmetic means so that total costs are 
preserved. Non-normality in errors will be allowed for by using generalised linear models 
with an appropriate error structure (for example, a gamma distribution [12]). Incremental 
cost-effectiveness ratios or an incremental cost-utility ratio will be presented where 
appropriate. Cost-effectiveness acceptability curves will be plotted to summarise the 
uncertainty in cost-effectiveness. 
Detailed study plan 
Selection of subjects 
The local transplant clinic database will be used to identify patients meeting the baseline 
inclusion and exclusion criteria. At the start of the trial, the entire population of transplant 
clinic attendees who meet the eligibility criteria are potentially eligible for recruitment. On 
subsequent screening rounds, patients who reach 12 months post-transplantation after the 
start of the trial will become eligible and these will be recruited before the next screening 
round. 
Informed consent 
Potentially eligible patients will be approached at a routine clinic appointment by the 
principal investigator (PI) or research nurses and given printed and verbal information about 
the trial. They will have the opportunity to return for a second consultation within a few days 
to give informed consent for recruitment into the study or to do this on their next routine 
appointment. Alternatively, eligible patients will be sent information about the study through 
the post, for discussion and consent at their next routine appointment. Following consent, full 
eligibility criteria will be reviewed. This may include testing for chronic viral diseases (if 
they have not been tested within the last 5 years) and pregnancy (if a patient’s history 
suggests there is the possibility of pregnancy). 
Inclusion criteria 
• Sufficient grasp of English language to give written and witnessed informed consent to 
participate 
• Renal transplant recipients >1 year post-transplantation, male or female 
• Aged 18 to 70 years 
• Estimated glomerular filtration rate (eGFR) ≥ 30, based on the four-variable Modification 
of Diet in Renal Disease (MDRD) approach 
Exclusion criteria 
• Recipient requiring HLA desensitisation to remove antibodies for a positive cross-match 
transplant 
• Recipient known already to have HLA antibodies who has received specific intervention 
for those antibodies or for CR 
• Recipient of an additional solid organ transplant (for example, pancreas, heart, etc.) 
• History of malignancy in previous 5 years (excluding non-melanomatous tumours limited 
to the skin) 
• Positive for hepatitis B surface antigens, hepatitis B core antibodies, hepatitis C or HIV 
(according to a test performed within the previous 5 years) 
• History of acute rejection requiring escalation of immunosuppression in the 6 months prior 
to screening 
• Patient enrolled in any other study involving administration of another investigational 
medical product (IMP) at time of recruitment 
The following exclusion criteria are based on the summaries of the product characteristics of 
the IMPs: 
• History of an ongoing or previous infection (no time limit) that would prevent optimisation 
of immunosuppression, including ocular herpes simplex 
• Known hypersensitivity to any of the IMPs 
• Known hereditary disorders of carbohydrate metabolism 
• Pregnancy or breastfeeding females (based on verbal history of recipient) 
• Pre-menopausal females who refuse to consent to using suitable methods of contraception 
throughout the trial 
Randomisation procedure and code break 
Prior to randomisation but after consent, site staff will register a recruit on the web-based 
electronic data capture system (InferMed MACRO), hosted at the King’s Clinical Trials Unit 
(KCTU). Each will be assigned a unique study patient identification number (PIN) by the 
system. Samples from all recruits will be sent to the HLA laboratory, along with this PIN and 
a sample request form containing other information required for randomisation. 
Laboratory staff will screen for HLA Ab and perform SAB testing on positive screening 
samples to check for the presence of DSA. Once this information is known, the lab staff will 
access the KCTU randomisation system and randomise the patient, using the HLA Ab results. 
Randomisation will be further stratified by centre and current immunosuppression. The lab 
staff, PIs and nurses at the site will be automatically emailed and the randomisation system 
will inform them whether the patient is in a blinded or unblinded group. If the patient is in an 
unblinded group, the system will inform the PI of the HLA Ab status. Unblinded patients will 
be identified by blue stickers appended to the notes and all future clinical samples. The 
system will tell the trial staff to enter HLA Ab– patients into the subsequent 8-monthly 
screening rounds, and also whether the patients have been selected to provide future samples 
for the 4-monthly scientific analysis (for transfer to the chief investigator’s laboratory). This 
information will be relayed using a star on the blue labels that are appended to the laboratory 
request forms. 
The notes and samples from blinded patients will have green stickers and labels. The HLA 
Ab status will not be given to the PIs or trial staff. A star will be used to tell the trial staff 
which recruits have been selected to provide 4-monthly samples for transfer back to the chief 
investigator’s lab for scientific analysis. These patients will have samples taken every 8 
months for HLA Ab screening. Once inside the lab, the lab staff will use their knowledge of 
the HLA status to determine which HLA Ab– patients will undergo screening. The samples 
from HLA Ab + patients will be discarded. 
On the second and subsequent HLA Ab screening rounds, the lab staff will update the 
randomisation system. The results from patients in the unblinded groups only will be 
forwarded to the PI and laboratory staff via email. This will indicate whether the status has 
changed, which will trigger the change in the treatment protocol for those that have changed 
from HLA Ab negative to positive. 
Laboratory staff at each recruiting site, with access to HLA Ab results, will be provided with 
a unique username and password to access the randomisation system. Password access must 
be authorised by the trial manager in all cases and direct requests from sites will not be 
processed. Access to the system is via the internet [13] by clicking the ‘randomisation – 
advanced’ link and selecting the OuTSMART Trial. 
There are no blinded study medications in the trial so no emergency code break is required. 
In the event that a study site clinician wishes to be made aware of blinded laboratory results, 
this must be discussed and agreed with the trial manager and the chief investigator in all 
cases. It is not anticipated that unblinding in this manner will be required and only in 
extraordinary circumstances would this be agreed. 
Trial medication 
All treatments will be introduced on the basis that they will be tailored to the individual 
patient, according to compliance, tolerance and achievement of target levels (for tac). Failure 
to tolerate one or more of the components of the protocol (or refusal to take any of the agents) 
will not be used as a reason for withdrawal from the study. 
Investigational medical products and dosing regimen 
The optimised treatment protocol in the two groups (B1 and B2 in Figure 1) with HLA Ab 
will be: 
• Mycophenolate mofetil twice, three times or four times per day, or enteric-coated 
mycophenolic acid twice per day, with the daily dose determined according to local unit 
guidelines. The patient will be stabilised on the maximum tolerated dose. 
• Tacrolimus once or twice per day, according to local unit preference, with dose titrated to 
achieve 12-hour post-dose levels of 4 µg/L to 8 µg/L (4 ng/mL to 8 ng/mL). The patient 
will be stabilised on the maximum tolerated dose that achieves these levels. 
• Prednisolone once per day. Starting at 20 mg for two weeks, then reducing by 5 mg once 
per day every two weeks down to their previous maintenance dose or 5 mg once per day. 
After consultation with the Medicines and Healthcare products Regulatory Agency (MHRA), 
we have confirmed that all these medicines will be classed as IMPs, whereas all others will 
not. Mycophenolate mofetil/mycophenolic acid is being used outside of its marketing 
authorisation (which states that it should be used with ciclosporin). However, because it is 
now used widely in combination with tacrolimus in most units in the UK, the two can be 
regarded as standard care. We therefore propose that the three drugs will not require labelling 
in line with annex 13 of the Rules Governing Medicinal Products in the European Union. 
This means the IMPs can be managed as normal, through a general practitioner or hospital 
prescription (as appropriate) and will not require special labelling, accountability, storage, 
etc. 
Concomitant medication 
Patients in all groups will have blood pressure controlled and total cholesterol lowered, using 
agents according to local unit guidelines and working to unit-defined targets. All other 
medication and treatment will be determined by local unit guidelines. 
Withdrawal of subjects 
Individual recruits can withdraw at any time for any reason. Failure to tolerate one or more 
components of the treatment will definitely not be seen as a reason to withdraw an individual 
participant from the trial but is to be anticipated as an integral part of individualising therapy. 
Recruitment of new participants to the study will be halted temporarily on the advice of the 
data monitoring and ethics committee if any of the following are noted: a patient death 
attributable to treatment or an unacceptable incidence of severe adverse events attributable to 
treatment (if occurring in >10% of patients). In both these instances, the trial will undergo 
urgent review by the data monitoring and ethics committee and the trial steering committee. 
The investigator has the right to withdraw patients from treatment with the study drug in the 
event of inter-current illnesses, adverse events, severe adverse events, suspected unexpected 
serious adverse reactions, protocol violations, cure, administrative reasons or other reasons. It 
is understood by all concerned that an excessive rate of withdrawals can render the study 
uninterpretable and unnecessary withdrawal of patients should be avoided. Should a patient 
decide to withdraw from the study, all efforts will be made to report the reason for 
withdrawal as thoroughly as possible. Should a patient withdraw from treatment with the 
study drug only, efforts will be made to obtain follow-up data, with the permission of the 
patient. 
Participants who wish to withdraw from treatment will be asked to confirm whether they are 
still willing to provide study-specific data and samples for scientific laboratory analysis 
according to the trial protocol. 
Expected duration of trial 
The trial is expected to recruit for 3 years. We estimated that the minimum number of 
individuals in each of groups C and D still HLA Ab– at the primary end point should be 627 
(see Figure 1). The recruitment target is to randomise 950 patients to each of these groups. 
This allows for the predicted dropout rate and the rate of antibody conversion with a margin 
of error. Patients will be followed up for a period of 3 years post-recruitment, except for 
patients in groups C and D who become Ab + during the initial 3 years of follow-up, who 
will transfer to the relevant Ab + group and be followed up for a further 3 years from the date 
of transfer. Therefore, the maximum amount of time that any single patient can remain in the 
study is 6 years. Communication of the need for an extended follow-up will be made at the 
final HLA screening round at month 32, after the primary outcome data have been collected, 
to avoid unblinding the HLA status in the blinded care arm. 
Trial procedures 
Synopsis 
A structured screening programme for IgG HLA Ab is proposed in patients who provide 
consent. Results obtained will initially be blinded to the transplant clinicians and patients. 
Patients will be randomised through the King’s Clinical Trials Unit and stratified: (1) DSA+, 
non-DSA + or HLA Ab–, (2) by current immunosuppression (tac alone, MMF alone, both tac 
and MMF, or neither tac nor MMF) and (3) recruiting study site. Patients in groups A1, A2 
and C (see flow diagram in Figure 1) will remain blinded to the results of their screening (as 
will their clinicians), whereas those in B1, B2 and D will learn whether they are HLA Ab + or 
Ab–. All recruits will undergo a final test for HLA Ab status as they reach the end of the 
study. The optimised treatment protocol for patients in the two groups with HLA Ab (B1 and 
B2) is outlined above. Patients in all groups will have blood pressure controlled and total 
cholesterol lowered, according to local unit guidelines. 
First visit 
Post consent, patients who have not been screened for HIV or hepatitis B/C within the last 5 
years will undergo additional screening tests for these viruses. Female patients who report 
they may be pregnant will have a blood test for beta-Human Chorionic Gonadotrophin levels. 
Once eligibility criteria have been met, the following baseline data will be recorded at 
recruitment: 
• Weight 
• Blood pressure 
• Sex 
• Ethnicity 
• Age 
• Date of birth 
• HLA type 
• HLA type of donor kidney (if known) 
• Any significant past medical history, including history of diabetes mellitus, cause of renal 
failure, details of previous transplants and cause of graft loss, evidence of sensitisation pre-
transplantation (panel reactive antibody and antibody specificities if known) 
• Medication including doses 
• PCR of urine sample 
All patients will then have blood taken for; 
• Baseline clinical parameters: full blood count (minimum haemoglobin, white cell count, 
platelets); biochemical series (creatinine, Na+, K+, bicarbonate, calcium, C-reactive 
protein, lipid profile, glucose); MDRD eGFR on latest creatinine; current calcineurin 
inhibitor 12-hour trough levels (as appropriate); total immunoglobulin levels 
• Scientific analyses: 50 to 60 mL blood for separation of peripheral blood mononuclear 
cells (PBMC) and 20 mL for serum storage 
• Analysis of HLA Ab status (10 mL clotted blood), as described above, which will allow 
randomisation to proceed 
All patients will be asked to complete questionnaires to assess attitudes to risk and adherence. 
Subsequent visits 
The optimised treatment protocol will be introduced within the first 3 months in those HLA 
Ab + patients allocated to this group. Recruits will be seen up to every two weeks during this 
period (a maximum of six extra clinic appointments are envisaged), though they should be on 
a maintenance dose of prednisolone 7 weeks after initiating optimisation. During this period 
they will have full blood count (as above), creatinine, Na+, K+, glucose, calcineurin inhibitor 
trough levels and blood pressure monitored according to the trial protocol. Once stabilised, 
they will be seen at least every 4 months in the transplant clinic. Patients allocated to all other 
groups will be seen at least every 4 months in the transplant clinic for formal study 
assessments. Patients may be seen at other times during this period, according to clinical 
need, but study assessments should be done within the time parameters established in the 
protocol. 
Once every 4 months the following will be recorded: 
• Weight 
• Blood pressure 
• Full blood count (minimum haemoglobin, white cell count, platelets) 
• Biochemical series (creatinine, Na+, K+, bicarbonate, calcium, C-reactive protein, glucose) 
• MDRD eGFR on latest creatinine 
• Calcineurin inhibitor trough levels 
• PCR of urine sample 
• Total immunoglobulin levels 
• Episodes of infection, malignancy or new DM 
• Episodes considered to be adverse events 
Every 12 months, each patient’s lipid profile will be measured. 
For all patients with HLA Ab, and a small cohort of patients without, separate blood samples 
will be taken for non-routine scientific analyses as above. Steps will be taken to ensure this 
sampling does not break the blinding of group allocations. Once every 8 months, HLA Ab– 
patients will undergo further screening for HLA Ab (see above). At the end of the study, all 
patients will undergo a final test for HLA Ab status. 
In recruits with living donors (known to them), the living donors will be invited to participate 
either by the recruit or directly by the study team, following consent from the recruit to 
inform donors of their participation in the study. Donors will attend the clinic at their 
convenience, where consent will be taken and blood (60 mL) taken for separation of PBMC, 
which will be stored in the research laboratory, identified only as from the donor of a 
particular study recruit. Donors may be asked to donate another aliquot of blood at another 
time within the next 3 years. 
Laboratory tests 
Human leukocyte antigen antibody analysis 
Serum prepared from 10 mL of blood will be used in the commercially available LABScreen 
tests (One Lambda, Canoga Park, CA) , containing fluorescently tagged beads coated with 
purified HLA antigens. All participating centres have Luminex equipment (Luminex Corp, 
Austin, Texas) for analysis of these tests and the skills to process samples and interpret 
results. Therefore, the tests will be performed in each of the centres. A sequential analysis of 
samples is planned, first to identify those with HLA Ab, using mixed class I and class II Ab 
screening beads coated with multiple different types of HLA. The manufacturer’s definition 
of positive and negative tests will be used when interpreting the results. In those patients with 
positive results, the specificity of the HLA Ab will be determined by SAB, coated with single 
HLA class I or class II antigens. As before, when interpreting the results, the manufacturer’s 
definition of positive and negative tests will be used. Any patient with a positive test for HLA 
Ab identified by SAB will be regarded as HLA Ab + for the trial if the mean fluorescence 
intensity (MFI) is ≥2,000. If the HLA Ab are directed against a mismatched donor HLA 
antigen, the patient will be assigned as DSA+. The number of DSA with MFI ≥ 2,000 will be 
used to define the Ab ‘burden’ of an individual. In the final analysis, correlations between 
HLA Ab burden and outcomes will be sought. Patients with SAB positivity that is difficult to 
label as DSA + or non-DSA + (because of insufficient data on donor mismatches, for 
instance), will be regarded as being non-DSA+. Patients with a positive reaction on screening 
but lacking reactivity with the SAB at the level described will be considered negative. Excess 
serum will be stored. The same screening will be undertaken for HLA Ab– patients every 8 
months, with the samples taken at a routine clinic appointment. 
Routine biochemical, haematological and calcineurin inhibitor trough analysis 
These will be performed by the local clinical laboratories and the results recorded as above. 
Scientific laboratory analysis 
A laboratory analysis will be performed at recruitment for all patients and then every 4 
months on patients with HLA Ab and a small cohort of patients who are HLA Ab–, chosen 
randomly at randomisation. Then, 60 to 80 mL blood will be taken and 20 mL for serum. The 
samples will be sent to the research laboratory of the chief investigator where the blood will 
be separated into PBMC and CD34+ cells. DNA and RNA will be extracted from a small 
number of cells and stored. All other cells will be stored in aliquots in liquid nitrogen until 
thawed for analysis. Serum samples will be stored at −80°C until thawed for analysis. The 
same process for preparing PBMC will be used for the samples from donors. 
Patients will also consent to analysis, for research purposes, of any stored serum, blood or 
tissue (such as transplant biopsies). This will apply for all existing and future samples taken 
for clinical reasons. In the case of future transplant biopsies, the patients will be asked to 
consent to having an extra core taken for transcriptome analysis. Subject to available funding, 
this will be stored in an appropriate medium and transported to the chief investigator’s 
laboratory for storage. 
Procedures for assessing efficacy parameters 
Graft failure is defined as the return to long-term dialysis or re-transplantation. This will be 
measured from the date of recruitment and will be reported for failure due to any cause. The 
date of restarting dialysis or re-transplantation will be recorded on the Case Report Form. 
Deteriorating renal function will be determined by linear regression analysis of the serial 
MDRD eGFRs from the point of recruitment (like that used by Dudley et al. [14]). 
Deterioration is defined as a negative slope. To be valid, the linear regression should yield an 
adjusted r2 ≥ 0.35 and have P ≤ 0.05 for the slope value. Stable renal function will be defined 
as serial MDRD eGFRs that are not significantly different from the horizontal baseline (that 
is, P > 0.05 on linear regression analysis). An improvement in renal function will be defined 
as a change in the slope so that it becomes positive. Serum creatinine levels and MDRD 
eGFR for the 12 months preceding recruitment and for the whole time patients are on the trial 
will be recorded on the CRF. 
Proteinuria is defined by the PCR of a urine sample and is significant if >50. The PCR will be 
recorded on the CRF. 
Acute rejection is defined by a combination of: (a) an acute rise in serum creatinine 
prompting a renal biopsy and (b) any pathology on the biopsy that meets the criteria for acute 
rejection, according to the latest BANFF criteria. The number of biopsies and the appropriate 
biopsy reports will be recorded on the CRF. 
A full economic evaluation will adopt a National Health Service (NHS) perspective. The 3-
year outcomes are the rates of: (1) graft failure, (2) patient survival, (3) graft dysfunction (see 
definition above), (4) acute rejection and (5) culture-positive infection, malignancy or 
diabetes, together with (6) EQ-5D, which is a patient-specific quality-adjusted life years 
(QALY) measurement. Cost-effectiveness will use (1) to (5) where (1) is the primary and the 
others are secondary outcomes. Cost-utility will be measured using (6) (the EQ-5D 
questionnaire). The net benefit per patient will be calculated by multiplying QALY by the 
assumed maximum willingness-to-pay for QALY (£20,000 per QALY) and subtracting the 
costs. The costs of all interventions will be obtained from Guy’s or estimated by identifying 
relevant categories of resource utilisation or measuring the volume of each category and 
multiplying by the average NHS resource costs [15] (and using British National Formulary 
and NHS reference lists). The costs of an intervention include the cost of screening beads and 
enhanced drug costs. 
Participants’ reporting of adherence will be assessed using the Medicines Adherence Report 
Scale (MARS) [16,17], a valid and reliable scale that has been previously used to assess 
adherence in renal transplant recipients [18,19]. Self-report measures have the advantage of 
being inexpensive and non-intrusive. However, it is known that self-reporting underestimates 
the true extent of non-adherence because of inherent self-presentational and recall biases. 
Self-presentational bias occurs when respondents may be reluctant to admit to non-adherence 
because they perceive a social contract where the expectation is one of high adherence. 
MARS takes steps to diminish this bias by sanctioning and normalising reports of non-
adherence. However, this does not totally remove the effect of self-presentational and recall 
biases that are inherent in all self-report measures. For this reason we will apply a combined 
approach to adherence assessment, where an initial categorisation of patients into high vs low 
on the basis of self-reporting is revised based on calcineurin inhibitor blood monitoring 
(carried out in routine management for patients prescribed tacrolimus or ciclosporin) and 
tablet counts (conducted for a sample of participants). In this approach, reports of low 
adherence are accepted as self-presentational biases that act in the opposite direction (reports 
of low adherence are more reliable than reports of high adherence [20,21]). Patients who 
report high adherence are reclassified to low adherence on the basis of calcineurin inhibitor 
trough results (for example, if levels are undetectable then the participant is assumed to be 
non-adherent) or tablet counts (for example, if there is a greater than 20% discrepancy 
between the actual and expected tablet count then the participant is reclassified as non-
adherent). 
To explore the potential antecedents to participants’ adherence behaviours, they will be also 
be asked to complete specially adapted versions of questionnaires relating to treatment 
intrusiveness, symptoms associated with immunosuppressants, beliefs about medicines [22], 
satisfaction with information about their medicines [23] and whether they are feeling anxious 
and/or depressed [24]. Questionnaires will be used to qualify perceptions of personal risk 
[25]. On the basis of survey responses, a small number of participants will be purposively 
selected (for example, those with positive and negative attitudes, and high and low adherers) 
for qualitative interview to explore their perception of risk and adherence behaviours in more 
depth. 
All patients taking part in the trial will be asked to complete all or some of the questionnaires 
at specified times. Questionnaires will be administered electronically. Respondents will 
complete a survey online whilst in a clinic, using an iPad or equivalent tablet device 
designated solely for this trial. Completed survey responses are stored on Qualtrics secure 
servers and can only be accessed using a login and password. Nothing will be recorded on the 
main trial CRFs. 
The questionnaires will be piloted with the first few participants recruited to the Guy’s site. 
These respondents will be asked to undergo cognitive interviewing whilst completing the 
survey, a technique used to ensure the validity of questionnaire items [26]. On the basis of 
this pilot, the questionnaire items may undergo minor modification. The ease of utility of the 
online survey and tablet device will also be evaluated during the pilot. 
Ethical approval 
The OuTSMART trial has been approved by the National Research Ethics Service 
Committee London, Hampstead, (REC number 12/LO/1759 on 14 January 2013) and by the 
MHRA (EudraCT number 2012-004308-36 on 24 December 2012). 
Discussion 
Research by others working in this area has mostly focussed on how to treat established CR. 
All reports consider small numbers of patients. Theruvath et al. reported 12-month 
stabilisation of kidney function in ¾ patients with kidney dysfunction due to CR associated 
with HLA Ab after transfer onto tac and MMF and a short course of prednisolone [27]. In 
addition, several studies have reported successful stabilisation of CR using B cell depletion 
therapy [28-30], further supporting the hypothesis that targeting underlying cellular 
responses, rather than HLA Ab, is a rational approach to treatment for these patients. 
Several other strands of evidence support the use of an optimised tac and MMF regime to 
prevent progression of CR. First, both MMF [31] and tac [32] are better at suppressing acute 
rejection than alternative agents and the combination of the two agents achieves better 
outcomes at 1 and 2 years compared to alternative regimes [33,34]. Second, regimes 
containing MMF are associated with a lower prevalence of HLA Ab [35] and MMF 
specifically reduces the development of HLA Ab during episodes of acute rejection [36]. 
Third, although these benefits have not always fed through to improvements in graft survival 
rates, one recent landmark study did show improved graft survival for a combination of tac 
and MMF [37]. For tac, enhanced graft survival also emerged during a systematic Cochrane 
review comparing tac with ciclosporin [34]. For MMF, a retrospective analysis of United 
States registry data revealed an association with significantly lower rates of premature 
allograft failure [38]. Finally, some studies have shown that conversion from ciclosporin to 
tac is beneficial for patients with deteriorating graft function [39], and that introduction of 
MMF has a similar effect [40]. Although other studies have reported contradictory results 
[41], much of this literature is difficult to interpret because many studies do not distinguish 
between CR and other causes of chronic graft dysfunction [42]. 
In addition to tac and MMF, we propose to use a short course of moderate-dose prednisolone 
followed by low dose steroid maintenance in this trial. There is no direct evidence from the 
transplant literature to support this intervention, but a similar treatment course is standard 
therapy in many situations where quick and effective suppression of immune responses is 
required, for example in acute asthma and in many types of autoimmune diseases. 
In summary, this trial will identify a group of patients at high risk of premature transplant 
failure. Therapy will be optimised for these at-risk patients, many of whom will be identified 
before they have started to deteriorate clinically. As described above, the natural history of 
untreated CR is of progressive loss of function, usually at a predictable rate, leading 
eventually to complete loss of graft function. Depending on the initial creatinine level, the 
time to graft loss will be variable, but graft loss rarely occurs without this period of 
progressive loss of function. Lachmann et al. [8] reported a constant rate of graft loss from 
the start of their study, so we expect that the rate of graft loss in our study will be constant in 
the standard care group. We predict that optimised immunotherapy will change the natural 
history of the condition, and lead to stabilisation of function in a significant proportion (50%) 
of those with HLA Ab. This will be visible in our analyses of the secondary end points. 
Hopefully the treatment will prevent the predicted graft loss in the first 3 years for this group 
and thus impact on the primary end point of the study. 
Trial status 
At the time of submission, the study has a planned recruitment start date of 27 August 2013. 
Endnotes 
a
 In the transplantation literature, this problem is called ‘late’ allograft failure, in which ‘late’ 
refers to the lifespan of the transplanted organ. We have changed the term to shift the 
emphasis to the recipient. 
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